

Special Issue

Pathophysiology of Chronic Kidney Disease and Its Complications, 2nd Edition

Message from the Guest Editor

The number of chronic kidney disease (CKD) patients is increasing worldwide. CKD is a risk for end-stage kidney disease requiring renal replacement therapy and is a leading cause of death. The pathogenesis of CKD is multifactorial, including podocyte and tubular damage, inflammation and fibrosis, oxidative stress, endothelial dysfunction and hypoxia, and is not fully understood. Therefore, exploring the underlying mechanisms of CKD will lead to the development of new therapies. Furthermore, CKD affects multi-organ systems such as cardiovascular diseases, bone abnormalities, muscle atrophy and cognitive function. These complications are closely related to the prognosis of CKD. Therefore, inter-organ crosstalk in CKD has been actively studied. The aim of this Special Issue is to elucidate the novel pathophysiology of CKD progression and its complications. Both research papers and review articles are welcome. We hope that the papers published in our journal will make a significant contribution to patients suffering from CKD.

Guest Editor

Dr. Yuji Oe

Division of Nephrology, Endocrinology, and Vascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan

Deadline for manuscript submissions

closed (31 October 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/182845

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).